Protein Engineering for Cardiovascular Therapeutics
نویسندگان
چکیده
منابع مشابه
MicroRNA therapeutics for cardiovascular disease
MicroRNAs (miRNAs) are short, single-stranded, noncoding RNAs that exert their function through annealing with complementary sequences in specific messenger RNAs (mRNAs) to inhibit their translation into proteins. Even though it was only a decade ago that the first human miRNA was discovered, therapeutics to regulate miRNA function are already entering the clinical space. The main reasons for t...
متن کاملAntibody Engineering and Therapeutics
note: The views expressed herein are those of the authors and do not necessarily reflect the views of their respective employers. Speakers who wrote a summary of their own presentation are listed in the header for the relevant session. The majority of the other summaries in this report were based on PDFs of the presentations provided by speakers or on post-meeting input from the speakers. The a...
متن کاملRNA Therapeutics for Treatment of Cardiovascular Diseases
Recent studies suggest that the majority of the human genome is transcribed, but only ≈2% account for protein coding exons. The remaining noncoding sequences include small noncoding RNAs, particularly microRNAs, which are ≈22 nucleotides in length. MicroRNAs posttranscriptionally control gene expression by targeting multiple mRNAs. By binding to the 3′UTR (untranslated region) of mRNAs, microRN...
متن کاملEngineering Ribonuclease - Based Cancer Therapeutics
............................................................................................................................ i Acknowledgements ............................................................................................................ iv Table of
متن کاملAntibody engineering and therapeutics conference
Half-day pre-conference workshops on three-dimensional (3D) structure antibody modeling and on identifying clonal lineages from next-generation data sets of expressed VH gene sequences will be held on Sunday December 8, 2013. The modeling workshop will be moderated by Juan Carlos Almagro (Pfizer, Inc and Gary L Gilliland (Janssen R&D, Inc. With the success of antibody-based therapeutics, protei...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Circulation Research
سال: 2013
ISSN: 0009-7330,1524-4571
DOI: 10.1161/circresaha.113.300215